LNFPIII has the value and potential for physiological function research and food market application. With the competent assistance of our researchers, CD BioGlyco provides clients with the fastest quality lacto-N-fucopentaose III (LNFPIII) products at a fair price, and we are always ready to take on production projects.

Requirements for Artificially Synthesizing LNFPIII

Human milk oligosaccharides (HMOs) have inhibitory effects on many pathogenic microorganisms and toxins. Most of them are oligosaccharides containing fucose residues, which account for about 28% of free oligosaccharides in human milk. LNFPIII, a pentasaccharide, is an important fucosylated oligosaccharide that exhibits many health effects. Because the free fucosylated oligosaccharide content in bovine and goat milk is not high, it is difficult to achieve large-scale production through extraction and purification. Adding artificially synthesized fucosylated oligosaccharides to the formula is necessary for infants who cannot be breastfed.

Immunomodulatory Effect of LNFPIII

Many studies have proved that LNFPIII often exhibits many important effects on the human body in terms of immune regulation. Some examples are as follows:

• Anti-inflammatory
  LNFPIII significantly decreases the severity of experimental autoimmune encephalomyelitis (EAE) and central nervous system inflammation by modulating both T-cell and innate immune responses, and it skews peripheral immune responses toward a Th2-dominant profile. In addition, LNFPIII reduces dendritic cell trafficking across brain endothelial cells in vitro.
• Alleviates hepatosteatosis and insulin resistance
  LNFPIII inhibits lipogenesis in the liver by up-regulating Nr1h4, thus preventing liver steatosis. Concurrently, it ameliorates insulin sensitivity and glucose tolerance in diet-induced obese mice.
• Lengthen the survival time of heart transplantation
  LNFPIII prolonged the survival of allografts in both vascularized and non-vascularized allograft models.
• As an immunodominant antigen in tumors
  As an immunodominant antigen, LNFP III is recognized in many human tumors, including gastrointestinal tract, urogenital tract and lung, adenocarcinoma of the breast; neuroblastoma; myeloid leukemia; and renal cell carcinoma. The associated expression may begin during the middle stages of infant development.

Fig.1 LNFPIII treatment suppresses EAE inflammation. (Zhu, et al., 2012)

LNFPIII Production Service at CD BioGlyco

CD BioGlyco supplies a variety of Methods that fully meet your production requirements for LNFPIII. We provide some optimization measures, including but not limited to the following:

• Constructing engineered Escherichia coli.
• Utilize the excellent fucosyltransferases in other bacteria.
• Generating enzyme variants to optimize reactions.
• Fed-batch culturing strains.

Advantages of Us

• Response specificity.
• Low-cost fermentative production.
• High-yield production.
• Rich resources of enzyme and bacterial resources.

As a recognized expert in the production of LNFPIII, CD BioGlyco has developed efficient and high-quality synthetic strategies. If you are interested in our services, please feel free to contact us.

Reference:

1. Zhu, B.; et al. Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis. Clinical immunology. 2012, 142(3): 351-361.